, Columnist
A 2018 Pharma Deal Revival Is No Sure Thing
The case for deals is even stronger this year than last, but lethargy may prevail again.
This article is for subscribers only.
Well, my prediction a year ago that biopharma M&A would rebound in 2017 didn't quite pan out.
Last year was the sector's third straight year of sequential deal-volume decline and the slowest since 2013. And the $95 billion deal total for the year is a little flattering -- 31 percent of that came from Johnson & Johnson's purchase of Actelion.